Roche Launches Liver Disease Panel, An Algorithm-Based Tool for Identifying and Managing CLD

Roche has announced the launch of its comprehensive Liver Disease Panel, a suite of certified algorithms designed to help clinicians better identify and manage chronic liver disease (CLD).

As described in a May 26, 2026, release from the Company, the tool brings together biomarker-based diagnostics and advanced digital algorithms, including the CE-marked algorithm LiverPRO, to support better-informed clinical decisions, from timely fibrosis risk identification to the surveillance of liver cancer.

“Chronic liver disease impacts millions of lives around the world, and patients need effective care at every stage of their journey,” Matt Sause, CEO of Roche Diagnostics, said in a statement. “With the Liver Disease Panel, we are enabling clinicians to identify risk earlier, intervene sooner, and manage this disease more effectively, helping to improve liver care and support better patient health.”

The Liver Disease Panel is Roche’s first comprehensive digital portfolio of biomarker and digital algorithm solutions designed to support care across key stages of the chronic liver disease pathway, from metabolic dysfunction-associated steatotic liver disease (MASLD) to metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC). Chronic liver disease is estimated to affect approximately 1.5 billion people worldwide, with MASLD accounting for the most common cause of prevalent disease.

This library brings together clinically validated algorithms into a single, secure platform. It combines tools like LiverPRO for likelihood of having liver fibrosis, ADAPT with Roche's Elecsys® PRO-C3 for assessing severity of liver fibrosis, and GAAD with Roche's Elecsys® AFP and Elecsys® PIVKA II for aid in diagnosis of HCC, with trusted clinical tools such as the FIB-4 Index, MELD Scores, ALBI Score, Child-Pugh Score, and the Lille Model.

Of note, LiverPRO has been endorsed in the EASL Patient Trajectory Guidance as an alternative and scalable first-line test for liver fibrosis, confirming that the tool standardizes patient referrals and speeds up the identification of high-risk cases using a non-invasive technology.

The Liver Disease Panel is available on the navify® Algorithm Suite and is intended to seamlessly integrate with existing hospital systems, giving clinicians a single point of access to order and view algorithm results.

Roche’s navify portfolio includes > 130 digital solutions for labs, hospitals and patients worldwide in commercial or research phases. The platform is designed to deliver security at every step of the data analytical process with ISO/IEC 27001 certification for the Information Security Management System. All data is encrypted at rest and in transit. The solution is operated in compliance with applicable laws and regulations in the US with Health Insurance Portability and Accountability as well as with General Data Protection Regulation regulations in Europe.

References

1. Roche. Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management. May 26, 2026. Accessed May 27, 2026. https://www.roche.com/media/releases/med-cor-2026-05-27

2. Cheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. Clin Liver Dis (Hoboken). 2021;17(5):365-370. doi:10.1002/cld.1061